Patient characteristics of those submitting and those not submitting MRD samples
| Characteristic . | Patients submitting MRD samples, total (%) . | Patients without MRD samples, total (%) . | P value . |
|---|---|---|---|
| Age, y | |||
| <10 | 31 (36.0) | 31 (25.2) | |
| 10-16 | 33 (38.4) | 59 (48.0) | .213 |
| ≥16 | 22 (25.6) | 33 (26.8) | |
| Sex | |||
| Male | 67 (77.9) | 92 (74.8) | .604 |
| Female | 19 (22.1) | 31 (25.2) | |
| CNS | |||
| CNS1 | 78 (90.7) | 118 (96.7) | .171 |
| CNS2 | 5 (5.8) | 3 (2.5) | |
| CNS3 | 3 (3.5) | 1 (0.5) | |
| Testicular disease | |||
| Yes | 2 (2.3) | 1 (0.8) | |
| No | 65 (75.6) | 91 (74.0) | .596 |
| N/A (female) | 19 (22.1) | 31 (25.2) | |
| Corticosteroid pretreatment | |||
| Yes | 22 (25.6) | 41 (33.3) | .229 |
| No | 64 (74.4) | 82 (66.7) | |
| Race | |||
| American Indian or Alaskan Native | 0 | 0 | |
| Asian | 2 (2.3) | 4 (3.2) | |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | |
| Multiple races | 1 (1.2) | 0 (0) | |
| Black or African American | 8 (9.3) | 28 (22.8) | .095 |
| White | 62 (72.1) | 76 (61.8) | |
| Unknown | 13 (15.1) | 15 (12.2) | |
| Ethnicity | |||
| Hispanic or Latino | 14 (16.3) | 18 (14.6) | .870 |
| Not Hispanic or Latino | 66 (76.7) | 98 (79.7) | |
| Unknown | 6 (7.0) | 7 (5.7) | |
| Bone marrow blasts | |||
| <1% Blasts | 51 (59.3) | 15 (12.2) | |
| 1%-5% Blasts | 29 (33.7) | 9 (7.3) | <.0001 |
| ≥5% Blasts | 2 (2.3) | 1 (0.8) | |
| Unknown | 4 (4.7) | 98 (79.7) | |
| Bone marrow MRD % day 29 | |||
| <0.01 | 71 (82.6) | ||
| 0.01 to <0.1 | 4 (4.6) | ||
| 0.1 to <1 | 6 (7.0) | ||
| 1 to <10 | 2 (2.3) | ||
| ≥10 | 3 (3.5) | ||
| Day 29 response | |||
| Complete response | 44 (51.6) | 44 (37.9) | |
| Partial response | 42 (48.4) | 40 (60.4) | .098 |
| Stable disease/no response | 0 | 2 (1.7) | |
| Risk group | |||
| Standard risk | 26 (30.2) | 63 (51.2) | |
| Intermediate risk | 58 (67.5) | 47 (38.2) | |
| Very high risk | 0 | 2 (1.6) | .0003 |
| No risk group | 2 (2.3) | 11 (9.0) | |
| Murphy stage | |||
| I | 1 (1.2) | 1 (0.8) | |
| II | 1 (1.2) | 1 (0.8) | .0004 |
| III | 17 (19.8) | 41 (33.3) | |
| IV | 19 (22.1) | 3 (2.5) | |
| Unknown | 48 (55.7) | 77 (62.6) |
| Characteristic . | Patients submitting MRD samples, total (%) . | Patients without MRD samples, total (%) . | P value . |
|---|---|---|---|
| Age, y | |||
| <10 | 31 (36.0) | 31 (25.2) | |
| 10-16 | 33 (38.4) | 59 (48.0) | .213 |
| ≥16 | 22 (25.6) | 33 (26.8) | |
| Sex | |||
| Male | 67 (77.9) | 92 (74.8) | .604 |
| Female | 19 (22.1) | 31 (25.2) | |
| CNS | |||
| CNS1 | 78 (90.7) | 118 (96.7) | .171 |
| CNS2 | 5 (5.8) | 3 (2.5) | |
| CNS3 | 3 (3.5) | 1 (0.5) | |
| Testicular disease | |||
| Yes | 2 (2.3) | 1 (0.8) | |
| No | 65 (75.6) | 91 (74.0) | .596 |
| N/A (female) | 19 (22.1) | 31 (25.2) | |
| Corticosteroid pretreatment | |||
| Yes | 22 (25.6) | 41 (33.3) | .229 |
| No | 64 (74.4) | 82 (66.7) | |
| Race | |||
| American Indian or Alaskan Native | 0 | 0 | |
| Asian | 2 (2.3) | 4 (3.2) | |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | |
| Multiple races | 1 (1.2) | 0 (0) | |
| Black or African American | 8 (9.3) | 28 (22.8) | .095 |
| White | 62 (72.1) | 76 (61.8) | |
| Unknown | 13 (15.1) | 15 (12.2) | |
| Ethnicity | |||
| Hispanic or Latino | 14 (16.3) | 18 (14.6) | .870 |
| Not Hispanic or Latino | 66 (76.7) | 98 (79.7) | |
| Unknown | 6 (7.0) | 7 (5.7) | |
| Bone marrow blasts | |||
| <1% Blasts | 51 (59.3) | 15 (12.2) | |
| 1%-5% Blasts | 29 (33.7) | 9 (7.3) | <.0001 |
| ≥5% Blasts | 2 (2.3) | 1 (0.8) | |
| Unknown | 4 (4.7) | 98 (79.7) | |
| Bone marrow MRD % day 29 | |||
| <0.01 | 71 (82.6) | ||
| 0.01 to <0.1 | 4 (4.6) | ||
| 0.1 to <1 | 6 (7.0) | ||
| 1 to <10 | 2 (2.3) | ||
| ≥10 | 3 (3.5) | ||
| Day 29 response | |||
| Complete response | 44 (51.6) | 44 (37.9) | |
| Partial response | 42 (48.4) | 40 (60.4) | .098 |
| Stable disease/no response | 0 | 2 (1.7) | |
| Risk group | |||
| Standard risk | 26 (30.2) | 63 (51.2) | |
| Intermediate risk | 58 (67.5) | 47 (38.2) | |
| Very high risk | 0 | 2 (1.6) | .0003 |
| No risk group | 2 (2.3) | 11 (9.0) | |
| Murphy stage | |||
| I | 1 (1.2) | 1 (0.8) | |
| II | 1 (1.2) | 1 (0.8) | .0004 |
| III | 17 (19.8) | 41 (33.3) | |
| IV | 19 (22.1) | 3 (2.5) | |
| Unknown | 48 (55.7) | 77 (62.6) |
CNS, central nervous system; N/A, not applicable.